Travel Vaccine

Travel Vaccine

The global travel vaccine ongoing and forthcoming encompasses vaccines manufactured for protecting travelers against diseases that are usually identifiable in diverse countries and are thus likely to affect travelers, these vaccines include Hepatitis A and B, typhoid, yellow fever, and rabies. Some of the forces that are currently fueling this market are the global traffic upsurge, improved consciousness of health risks associated with traveling, and official health guidelines and requirements from various governments and health institutions. Also, new technologies, new disease threats, and developments in travel-related infrastructures added to the market growth, so, traveling vaccinations are a key part of travel requirements.

The market for travel vaccine market is set to exhibit a growth rate of about 9.5%. This is mainly due to the rise in surgical procedures, especially orthopedic surgeries, which increases the need for DVT prophylaxis and treatment. Also, innovations in vaccine development and delivery systems enhance the efficacy and accessibility of travel vaccines. This will further boost market growth. For instance, In December 2021, Emergent BioSolutions Inc. declared the first participant dosed in its phase 1 study, EBS-UFV-001, studying the safety, tolerability, and immunogenicity of its investigational universal influenza vaccine candidate. The current and updated version of this influenza vaccine candidate includes multiple components intended to induce broad and supra-seasonal immunity against influenza A viruses.

• Based on the disease type, the market is segmented into hepatitis, typhoid, influenza, DPT, yellow fever, and others. The hepatitis category is expected to have the largest market share of the travel vaccine market due to the increased risks of Hepatitis A and B in most tourism; especially those in the developing world. The traveling public seeks these vaccines because of the recommendations and in some cases, requirements of such health organizations and countries. These are awareness campaigns, corporate travel policies, and the emergence of international travel also catalyzed this growth. Further, accessibility of Hepatitis vaccines, safety, and efficacy also add to the high demand for Hepatitis vaccines midst travelers while government participation in touting travel health assessments contributes towards the formulation of travel health measures hence the vaccines in question form a significant cog in travel health.
• Based on the tourist type, the market is segmented into domestic and international. Among these, the domestic category is expected to have the largest market share of the travel vaccine market due to the rising number of times that people visit different areas in their own countries, which puts them at different risks of getting diseases. Domestic tourists move from one region to another or from urban areas to rural areas or areas where the diseases are endemic and therefore, they require vaccinations of the diseases that are prevalent in the region they are visiting such as tick-borne encephalitis or typhoid fever. Due to government campaigns espousing local tourism as well as the post-pandemic increased concerns for health, people travel domestically within their countries and are likely to get vaccinated to ensure safe travels. This trend has a positive impact on the overall demand for travel vaccines and thus fuels the growth of the global market.
• Based on the age group, the market is segmented into pediatrics, adults, and geriatrics. Among these, the adult category segment also significantly boosts the travel vaccine market. Adults, especially those between 18 and 60, constitute a major portion of the traveling population for both leisure and business purposes. This demographic is more likely to travel to international destinations, including regions with higher health risks, necessitating vaccinations for diseases like yellow fever, Hepatitis A and B, and typhoid. Additionally, as adults are typically responsible for their health decisions, they are more likely to adhere to vaccination recommendations. The increasing trend of solo travel and adventure tourism among adults further elevates the need for comprehensive vaccination, driving market growth.
• For a better understanding of the market adoption of travel vaccines, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. The North American travel vaccine market is characterized by robust demand driven by a high volume of international travel, stringent health regulations, and increasing awareness of travel-related health risks. The region's market is bolstered by established healthcare infrastructure, widespread availability of vaccines, and proactive vaccination policies recommended by health authorities such as the CDC. Companies in North America focus on offering comprehensive vaccine portfolios, leveraging advanced healthcare technologies for distribution, and emphasizing traveler education to ensure widespread adoption of vaccinations. The market's growth is further propelled by rising outbound tourism and business travel, highlighting the region's pivotal role in global travel health initiatives.
• Some of the major players operating in the market include Merck & Co., Inc.; Sanofi; Novartis AG; Pfizer Inc.; EMERGENT; Abbott; Serum Institute of India Pvt. Ltd.; Takeda Pharmaceutical Company Limited; AstraZeneca; and GSK plc.